Macrogenics (MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

February 6, 2019 7:55 AM

Macrogenics (NASDAQ: MGNX) Climbs ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found